Ontology highlight
ABSTRACT: Purpose
The aim of this study was to evaluate the ability of a 41-gene signature derived from breast cancer stem cells (BCSCs) to estimate the risk of metastasis and survival in breast cancer patients.Methods
The centroid expression of the 41-gene signature derived from BCSCs was applied as the threshold to classify patients into two separate groups--patients with high expression (high-EL) of the prognostic signature and patients with low expression (low-EL). The predictive ability of the 41-gene signature was evaluated by Cox regression model and was compared against other popular tests, such as Oncotype and MammaPrint.Results
Our results showed that the 41-gene prognostic signature was significantly associated with age (P = .0351) and ER status (P = .0095). The analysis indicated that patients in the high-EL group had a worse prognosis than those in the low-EL group in terms of both overall survival (OS: HR, 2.05, P = .009) and distant metastasis-free survival (DMFS: HR, 2.24, P = .002). Additionally, the 41-gene signature was an independent risk factor and separates patients based on estrogen receptor status. While comparable to Oncotype, the analysis demonstrated that the 41-gene signature had a better prognostic value in predicting DMFS and OS than AOL, NPI, St. Gallen, Veridex, and MammaPrint.Conclusions
This study confirms the utility of the 41-gene signature and adds to the growing evidence that gene expression signatures of BCSCs have clinical potential to predict patient outcome and aid in treatment choice.
SUBMITTER: Yin ZQ
PROVIDER: S-EPMC4229870 | biostudies-literature | 2014 Jun
REPOSITORIES: biostudies-literature
Yin Zhi-Qiang ZQ Liu Jian-Jun JJ Xu Ying-Chun YC Yu Jian J Ding Guo-Hui GH Yang Feng F Tang Lei L Liu Bao-Hong BH Ma Yue Y Xia Yu-Wei YW Lin Xiao-Lin XL Wang Hong-Xia HX
Journal of experimental & clinical cancer research : CR 20140606
<h4>Purpose</h4>The aim of this study was to evaluate the ability of a 41-gene signature derived from breast cancer stem cells (BCSCs) to estimate the risk of metastasis and survival in breast cancer patients.<h4>Methods</h4>The centroid expression of the 41-gene signature derived from BCSCs was applied as the threshold to classify patients into two separate groups--patients with high expression (high-EL) of the prognostic signature and patients with low expression (low-EL). The predictive abili ...[more]